Phenylpyrrole compounds in Codonopsis pilosula, their preparation methods and applications, and pharmaceutical compositions

By extracting and separating the phenylpyrrole compounds Codonopsis pilosula N and Codonopsis pilosula A from Codonopsis pilosula, the problem of poor efficacy of existing hypoglycemic drugs has been solved. High-purity compounds and significant α-glucosidase inhibitory effects have been achieved, showing broad application prospects for hypoglycemic drugs.

CN123106500APending Publication Date: 2026-11-17NORTHWEST INST OF PLATEAU BIOLOGY CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611334427.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-31
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The hypoglycemic efficacy of existing hypoglycemic drugs still needs to be further improved, and there is an urgent need to extract and isolate new compound components from Codonopsis pilosula to develop more effective hypoglycemic drugs.

Method used

The phenylpyrrole compounds codonopsis pilosula N and codonopsis pilosula A were extracted and separated from Codonopsis pilosula using a method of ethanol reflux extraction, D101 macroporous adsorption resin elution, MCI GEL gradient elution, C18 reverse chromatographic column chromatography, and ODS C18 column separation. The compounds were purified and enriched by elution steps with different polarities.

Benefits of technology

Codonopsis pilosulae N and Codonopsis pilosulae A with a purity of up to 95.4% were successfully extracted and separated, exhibiting excellent α-glucosidase inhibition rate and significantly improving the hypoglycemic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106500A_ABST
    Figure CN123106500A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of traditional Chinese medicine extraction and separation technology, specifically relating to a phenylpyrrole compound from Codonopsis pilosula, its preparation method, application, and pharmaceutical composition. This invention provides a phenylpyrrole compound isolated from Codonopsis pilosula, wherein the phenylpyrrole compound is a pair of epimers with the molecular formula C0. 13 H 19 NO5, named Codonopsis pilosulae N and Codonopsis pilosulae A, respectively. The structures of these compounds were determined using proton NMR, carbon NMR, two-dimensional NMR, and high-resolution mass spectrometry. The phenylpyrrole compounds of this invention possess excellent α-... ‑ It has a glucosidase inhibition rate, which has a hypoglycemic effect and can be used to prepare hypoglycemic drugs for the treatment of diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine extraction and separation technology, specifically relating to a phenylpyrrole compound from Codonopsis pilosula, its preparation method and application, and a pharmaceutical composition thereof. Background Technology

[0002] Codonopsis pilosula is a traditional Chinese medicinal herb. It is a plant belonging to the genus Codonopsis of the family Campanulaceae. Codonopsis pilosula (Franch.) Nannf., Codonopsis pilosula (Western Codonopsis pilosula) Codonopsis pilosula Nannf. var. modesta (Nannf.) LTShen or Codonopsis pilosula Codonopsis tangshen The dried roots of *Codonopsis pilosula* are mainly distributed in Yunnan, Sichuan, Guizhou, Tibet, Qinghai, Gansu, and Shanxi provinces. They are found in mountainous forests and thickets at altitudes of 1560-3100 meters in northern China. They are commonly used to treat spleen deficiency, lung weakness, shortness of breath, palpitations, asthma, cough, and diabetes. *Codonopsis pilosula* contains abundant chemical components, mainly polyacetylenes, flavonoids, alkaloids, phenolic acids, polysaccharides, terpenoids, and coumarins.

[0003] In recent years, in order to explore the potential of Codonopsis pilosula in lowering blood sugar and apply it to the treatment of diabetes, in-depth research has been conducted on the chemical composition of Codonopsis pilosula, and more and more components and their bioactivities have been disclosed. At present, the hypoglycemic efficacy of existing hypoglycemic drugs still needs to be further improved, and there is an urgent need to develop Codonopsis pilosula and extract and isolate new compound components from it. Summary of the Invention

[0004] To address the above problems, this invention provides a novel phenylpyrrole compound extracted and isolated from Codonopsis pilosula, which possesses excellent α-properties. - Its glucosidase inhibition rate is higher than that of existing hypoglycemic drugs, and its hypoglycemic effect is superior.

[0005] To achieve the objectives of this invention, the following technical solutions are provided: A phenylpyrrole compound with the molecular formula C 13 H 19 NO5, which is either codonopsis alkaloid N or codonopsis alkaloid A, has the following chemical structural formula: , ; Codonopsis pilosula N and Codonopsis pilosula A are epimers of each other.

[0006] This invention provides a method for extracting and separating phenylpyrrole compounds as described above, comprising the following steps: Step 1: Extract the root of Codonopsis pilosula by reflux with ethanol, concentrate the extract to obtain an extract; Step 2: Elute the extract onto the macroporous adsorption resin sequentially with water and ethanol aqueous solution, collect the ethanol aqueous solution eluent, and concentrate it; Step 3: Load the concentrated ethanol-water eluent onto an MCI GEL column, use an alcohol-water gradient elution system, and collect the fractions. Step 4: Separate fraction Fr.6 by C18 reverse chromatographic column chromatography, using the first alcohol-water mobile phase for elution, to obtain fractions Fr.6-3 and Fr.6-4; the fraction Fr.6 is obtained by using an alcohol-water system with an alcohol volume fraction of 25%~28.5%; Step 5: Separate component Fr.6-3 by ODS C18 column chromatography, using the second alcohol-water mobile phase as the first elution to obtain codonopsis alkaloid N; separate component Fr.6-4 by Xunion C18 column chromatography, using the third alcohol-water mobile phase as the second elution to obtain codonopsis alkaloid A.

[0007] Preferably, the volume concentration of ethanol in step one is 70-80%, and the ratio of the dry weight of the Codonopsis root to the amount of ethanol is 16 kg: 150-250 L.

[0008] Preferably, the macroporous adsorption resin in step two is D101 macroporous adsorption resin, and the volume concentration of ethanol in the ethanol aqueous solution is 15~25%.

[0009] Preferably, the alcohol-water system in step three is a methanol-water system, and the gradient elution program is as follows: 0~30 min, methanol volume fraction is 0%; 30~210 min, methanol volume fraction increases from 0% to 32%; 210~211 min, methanol volume fraction increases from 32% to 40%; 211~240 min, methanol volume fraction increases from 40% to 95%; 240~270 min, methanol volume fraction is 95%; the flow rate of the gradient elution is 28~32 mL / min.

[0010] Preferably, in step four, the stationary phase of the C18 reverse-phase chromatography column is ODS C18; the first alcohol-water mobile phase is a methanol-water mobile phase; the elution is isocratic elution; the volume ratio of methanol to water in the methanol-water mobile phase is 11:89; the retention time of component Fr.6-3 is 15.093 min; and the retention time of component Fr.6-4 is 17.173 min.

[0011] Preferably, in step five, the second and third alcohol-water mobile phases are methanol-water mobile phases, the first and second elutions are isocratic elutions, the volume ratio of methanol to water in the methanol-water mobile phase is 5:95, the retention time of codonopsis alkaloid N is 9.282±0.2 min, the purity is >90%, and the yield is 8.4%; the retention time of codonopsis alkaloid A is 10.127±0.2 min, the purity is >90%, and the yield is 9.5%.

[0012] This invention provides phenylpyrrole compounds described in the above technical solution or phenylpyrrole compounds obtained by the above separation and extraction method in the preparation of α- - Applications of glucosidase inhibitors.

[0013] This invention provides the application of the phenylpyrrole compounds described in the above technical solution or the phenylpyrrole compounds obtained by the above separation and extraction method in the preparation of drugs for treating diabetes.

[0014] The present invention provides a pharmaceutical composition comprising the phenylpyrrole compound described in the above technical solution or the phenylpyrrole compound obtained by the separation and extraction method described therein, and pharmaceutically acceptable excipients.

[0015] This invention provides a pair of epimers of phenylpyrrole compounds derived from Codonopsis pilosula, with the molecular formula C0. 13 H 19 NO5, the phenylpyrrole compounds are named Codonopsis pilosulae N and Codonopsis pilosulae A, respectively. The phenylpyrrole compounds provided by this invention possess excellent α-... - The glucosidase inhibition rate has a hypoglycemic effect, and the phenylpyrrole compounds described in this invention can be used as effective components in the preparation of hypoglycemic drugs for the treatment of diabetes.

[0016] This invention provides a method for the extraction and separation of phenylpyrrole compounds. The method involves sequential extraction with ethanol reflux, elution with macroporous adsorption resin, elution with an MCI GEL column, separation by reversed-phase chromatography, and elution with an ODS C18 column and a Xunion C18 column, successfully extracting and separating two compounds. The method comprises only five steps, is simple and rapid, and primarily uses conventional reagents such as ethanol, methanol, and water. The process is simple and environmentally friendly. The purity of the separated Codonopsis pilosulae N was 95.4%, with a yield of 8.4%; the purity of Codonopsis pilosulae A was 94.7%, with a yield of 9.5%. Attached Figure Description

[0017] Figure 1 Key to Codonopsis N and Codonopsis A 1 H- 1 Related diagrams of H COSY, HMBC, and NOESY; Figure 2 High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) image of codonopsis alkaloid N; Figure 3 The proton NMR spectrum of codonopsis alkaloid N ( 1 H-NMR spectrum; Figure 4 The carbon NMR spectrum of codonopsis alkaloid N ( 13 C-NMR spectrum; Figure 5 The heteronuclear single quantum coherence (HSQC) spectrum of codonopsis alkaloid N; Figure 6 The heteronuclear multibond coherence spectrum (HMBC) of codonopsis pilosula N is shown. Figure 7 The hydrogen-hydrogen correlation spectrum of codonopsis alkaloid N ( 1 H- 1 HCOSY diagram; Figure 8 The nuclear Overhauser effect spectrum (NOESY) of codonopsis pilosula N is shown. Figure 9 Codonopsis alkaloid A 1 H-NMR spectrum; Figure 10 Codonopsis alkaloid A 13 C-NMR spectrum; Figure 11 The NOESY diagram for codonopsis alkaloid A; Figure 12 Codonopsis pilosula N and Codonopsis pilosula A and acarbose for α - IC50 glucosidase inhibitory activity 50 Value measurement curve. Detailed Implementation

[0018] This invention provides a phenylpyrrole compound with the molecular formula C 13 H 19 NO5, which is either Codonopsinol N or Codonopsinol A, has the following chemical structural formula: , ; Codonopsis pilosula N and Codonopsis pilosula A are epimers of each other.

[0019] This invention provides a method for extracting and separating phenylpyrrole compounds as described in the above technical solution, comprising the following steps: Step 1: Extract the root of Codonopsis pilosula by reflux with ethanol, concentrate the extract to obtain an extract; Step 2: Elute the extract onto the macroporous adsorption resin sequentially with water and ethanol aqueous solution, collect the ethanol aqueous solution eluent, and concentrate it; Step 3: Load the concentrated ethanol-water eluent onto an MCI GEL column, use an alcohol-water gradient elution system, and collect the fractions. Step 4: Separate fraction Fr.6 by C18 reverse-phase chromatography using a first alcohol-water mobile phase to obtain fractions Fr.6-3 and Fr.6-4; the fraction Fr.6 is obtained using an alcohol-water system with an alcohol volume fraction of 25%~28.5%. Step 5: Separate component Fr.6-3 by ODS C18 column chromatography, using the second alcohol-water mobile phase as the first elution to obtain codonopsis alkaloid N; separate component Fr.6-4 by Xunion C18 column chromatography, using the third alcohol-water mobile phase as the second elution to obtain codonopsis alkaloid A.

[0020] In this invention, unless otherwise specified, all raw materials used in the preparation are preferably commercially available products known to those skilled in the art.

[0021] This invention involves reflux extraction of Codonopsis pilosula root with ethanol, followed by concentration of the extract to obtain a paste. In one embodiment of this invention, prior to reflux extraction, the Codonopsis pilosula root is preferably dried and cut into segments of 2-5 cm in size to ensure sufficient contact between the root segments and the ethanol, resulting in more complete and stable extraction of the active ingredients. Before reflux extraction, the Codonopsis pilosula root is soaked at 25°C for 12 hours.

[0022] In one embodiment of the present invention, the volume concentration of ethanol can be 70-80%, specifically 75%. The present invention limits the ethanol concentration to selectively extract active ingredients and reduce the extraction rate of impurities. The ratio of Codonopsis pilosula root to ethanol is 16kg:150-250L, specifically 16kg:200L, to ensure that the ethanol fully soaks the Codonopsis pilosula root, so that the effective ingredients are fully dissolved, while avoiding excessive ethanol which would lead to high costs and affect subsequent concentration.

[0023] In one embodiment of the present invention, the reflux extraction temperature is 60~65℃, specifically 60℃, and the extraction is performed 2~4 times, specifically 3 times; the concentration temperature is 55~65℃, specifically 60℃, the concentration pressure is 11kPa, and the concentration ends when almost no solvent drips from the condenser.

[0024] After obtaining the extract, the present invention elutes the macroporous adsorption resin on the extract sequentially with water and ethanol aqueous solution, collects the ethanol aqueous solution eluent, and concentrates it.

[0025] In one embodiment of the present invention, the macroporous adsorption resin is D101 macroporous adsorption resin, and the volume concentration of the ethanol aqueous solution is 15-25%, specifically 20%. The present invention uses water and a 15-25% ethanol aqueous solution sequentially for elution, utilizing the adsorption-desorption differences of the resin for different polar components to achieve the separation, purification, and enrichment of the target active ingredient. The extract contains many inorganic salts, sugars (monosaccharides, disaccharides), amino acids, some hydrophilic pigments, proteins, and other strongly polar components. These components have weak adsorption with the resin. Therefore, the present invention first uses water for elution, as water has high polarity and can wash away strongly polar impurities. The main active ingredients in Codonopsis pilosula root remain on the resin. In this invention, a 15-25% ethanol aqueous solution is used for elution, with the polarity matching that of the main active ingredients, to elute the main active ingredients from the resin. The 15-25% ethanol aqueous solution eluent is collected and concentrated to obtain a concentrated ethanol aqueous solution eluent for subsequent separation. The concentration pressure is 9-10 kPa and the temperature is 50-55℃. The concentration ends when almost no solvent drips from the condenser.

[0026] This invention involves loading concentrated ethanol-water solution eluent onto an MCI GEL column, employing a gradient elution with an alcohol-water system, and collecting the fractions. In one embodiment, the MCI GEL column is a reverse-phase column, the alcohol-water system is an anhydrous methanol-water system, and the gradient elution program is as follows: 0–30 min, methanol volume fraction 0%; 30–210 min, methanol volume fraction increasing from 0% to 32%; 210–211 min, methanol volume fraction increasing from 32% to 40%; 211–240 min, methanol volume fraction increasing from 40% to 95%; 240–270 min, methanol volume fraction 95%. The flow rate for the gradient elution is 28–32 mL / min, specifically 30 mL / min.

[0027] In this invention, the packing material of the MCI chromatographic column is non-polar. In the methanol-water system, water is highly polar, while methanol is less polar than water. During gradient elution, the initial phase is low methanol and high water, with a highly polar mobile phase. The highly polar components in the concentrated low-concentration ethanol eluent will be eluted with the mobile phase. As the proportion of methanol increases, the polarity of the mobile phase gradually decreases, and the less polar components in the concentrated low-concentration ethanol eluent will be eluted. Under this gradient, the components in the concentrated low-concentration ethanol eluent are eluted and separated according to their polarity from high to low.

[0028] In this invention, fraction Fr.6 is separated by C18 reverse chromatographic column chromatography and eluted with a first alcohol-water mobile phase to obtain fractions Fr.6-3 and Fr.6-4; the fraction Fr.6 is obtained by using an alcohol-water system with an alcohol volume fraction of 25% to 28.5%.

[0029] In one embodiment of the present invention, the stationary phase of the C18 reverse-phase chromatographic column is ODS C18; the first alcohol-water mobile phase is a methanol-water mobile phase, the elution is isocratic elution, and the volume ratio of methanol to water in the methanol-water mobile phase is 11:89; the polarity index of commonly used solvents from smallest to largest is: n-hexane 0.0, petroleum ether ≈0.01, cyclohexane 0.1, isopropanol 3.9, tetrahydrofuran 4.0, chloroform 4.1, ethanol 4.3, ethyl acetate 4.4, acetone 5.1, methanol 5.1, acetonitrile 5.8, and water 10.2. Therefore, the methanol-water mobile phase has a relatively strong polarity; the present invention adopts isocratic elution, fixes the volume ratio of methanol to water in the mobile phase, and washes the chromatographic column with the mobile phase of fixed polarity. The components on the chromatographic column adsorb and desorb between the stationary phase and the mobile phase according to their own polarity. Finally, the components are eluted and separated from the chromatographic column in descending order of polarity. The retention time of component Fr.6-3 was 15.093 min, and the retention time of component Fr.6-4 was 17.173 min.

[0030] In this invention, the component Fr.6-3 is separated by ODS C18 column chromatography and eluted with a second alcohol-water mobile phase to obtain Codonopsis pilosulae N; the component Fr.6-4 is separated by Xunion C18 column chromatography and eluted with a third alcohol-water mobile phase to obtain Codonopsis pilosulae A. In one embodiment of the present invention, component Fr.6-3 uses a second alcohol-water mobile phase, namely a methanol-water mobile phase, and the first elution is isocratic elution. The volume ratio of methanol to water in the methanol-water mobile phase is 5:95, yielding codonopsis alkaloid N. The retention time of codonopsis alkaloid N is 9.282±0.2 min, the purity is >90%, and the yield is 8.4%. Component Fr.6-4 uses a third alcohol-water mobile phase, namely a methanol-water mobile phase, and the second elution is isocratic elution. The volume ratio of methanol to water in the methanol-water mobile phase is 5:95, yielding codonopsis alkaloid A. The retention time of codonopsis alkaloid A in step five is 10.127±0.2 min, the purity is >90%, and the yield is 9.5%.

[0031] The ultraviolet absorption spectra of Codonopsis N and Codonopsis A have a maximum absorption peak at 200 nm, characteristic absorption peaks at 233 nm and 280 nm, and absorption valleys at 220 nm and 257 nm.

[0032] This invention provides the phenylpyrrole compounds described in the above technical solution or the phenylpyrrole compounds obtained by the above separation and extraction method in the preparation of α-phenylpyrrole compounds. - Applications of glucosidase inhibitors.

[0033] Phenylpyrrole compounds inhibit enzyme activity by competitively or non-competitively blocking substrate binding and catalytic hydrolysis through π-π stacking and hydrogen bonding interactions with amino acid residues in the active site of yeast α-glucosidase via their hydrophobic phenyl and pyrrole rings.

[0034] This invention provides the application of the phenylpyrrole compounds described in the above technical solution or the phenylpyrrole compounds obtained by the above separation and extraction method in the preparation of drugs for treating diabetes.

[0035] The present invention provides a pharmaceutical composition comprising the phenylpyrrole compound described in the above technical solution or the phenylpyrrole compound obtained by the separation and extraction method described therein, and pharmaceutically acceptable excipients.

[0036] In one embodiment of the present invention, the effective content of phenylpyrrole compounds in the pharmaceutical composition is 30%, the pharmaceutically acceptable excipients include starch, microcrystalline cellulose, magnesium stearate, and colloidal silica, and the dosage form of the pharmaceutical composition includes tablets.

[0037] To further illustrate the present invention, the technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments thereof. Obviously, the described embodiments are merely some embodiments of the present invention, and not all embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0038] Example 1 Take 16 kg of dried Codonopsis pilosula root and cut it into 2-5 cm sections. Soak it at 25℃ for 12 hours. After soaking, extract the Codonopsis pilosula sections three times with 200 L of 75% ethanol at 60℃ using a YZTN-300 reflux extraction device. Concentrate 10 L of the extract under reduced pressure at 60℃ and 11 kPa until almost no solvent drips from the condenser, and obtain 12.8 kg of extract.

[0039] The extract was coarsely separated using D101 macroporous adsorption resin. After adsorption by the macroporous adsorption resin, it was eluted sequentially with water and 20% ethanol aqueous solution. The extract was then concentrated under reduced pressure at 50°C and 10 kPa to obtain two components (water-DS and 20% EtOH-DS).

[0040] 52.93 g of the 20% EtOH-DS fraction was separated by passing it through an MCI column using a methanol-water gradient elution system. The gradient elution program was as follows: 0–30 min, methanol volume fraction 0%; 30–210 min, methanol volume fraction increasing from 0% to 32%; 210–211 min, methanol volume fraction increasing from 32% to 40%; 211–240 min, methanol volume fraction increasing from 40% to 95%; 240–270 min, methanol volume fraction 95%, with a flow rate of 30 mL / min. A total of 9 fractions (Fr.1–Fr.9) were collected.

[0041] The collected fraction 6 (Fr.6, 4.548 g) was eluted isocratically with 11% methanol aqueous solution on an ODS C18 column to separate Fr.6-3 (178.1 mg, retention time 15.093 min) and Fr.6-4 (84 mg, retention time 17.173 min).

[0042] Fr.6-3 was eluted isocratically with 5% methanol aqueous solution on an ODS C18 column to obtain Codonopsis pilosula N (10 mg, retention time 9.282 min). Fr.6-4 was eluted isocratically with 5% methanol aqueous solution on a Xunion C18 column to obtain Codonopsis pilosula A (6 mg, retention time 10.127 min).

[0043] Both codonopsis alkaloid N and codonopsis alkaloid A are white powders with a mass-to-charge ratio (m / z) of 268.3081 [MH]. - The molecular formula is C 13 H 19 NO5.

[0044] The purity of the isolated codonopsis alkaloid N was 95.4%, and the yield was 8.4%; the purity of codonopsis alkaloid A was 94.7%, and the yield was 9.5%.

[0045] use 1 H NMR, 13 The structures of the isolated compounds were identified by 12C NMR spectroscopy, 2D NMR spectroscopy, and high-resolution mass spectrometry. The results are shown in Table 1 and 2012. Figure 1-11 As shown.

[0046] Table 1 Codonopsis pilosula N and Codonopsis pilosula A 1 H-NMR (600MHz) and 13 C-NMR (151MHz) spectral data

[0047] According to Table 1 and Figures 1-11The results confirm that the structures of codonopsis alkaloid N and codonopsis alkaloid A extracted and separated in this invention are as follows: , .

[0048] Test Example 1: α - Study on glucosidase inhibitory activity Codonopsis pilosula N (compound 1), Codonopsis pilosula A (compound 2), and the positive control drug acarbose (25 μmol / L, 50 μmol / L, 100 μmol / L, 150 μmol / L, 200 μmol / L, 250 μmol / L, 300 μmol / L, 375 μmol / L) were respectively subjected to IC50 assay. 50 Determination of the value; under ice bath conditions, 50 μL of α-saccharide derived from Saccharomyces cerevisiae was added. - Glucosidase (1 U / mL) (purchased from Sigma) and 50 μL of sample were mixed in a 96-well plate and incubated at 37°C with a shaking rate of 600 rpm / min for 10 min. Then, 50 μL of 0.5 mmol / L pNPG (for detecting α) was added. - The glucosidase activity was added to the above mixture and incubated at 37°C with a shaking rate of 600 rpm / min for 20 min; finally, 50 μL of 0.1 mol / L Na₂CO₃ solution was added to terminate the reaction, and each group was repeated three times; the absorbance (A value) was measured at 409 nm, and the sample's activity against α was calculated. - The inhibitory activity of glucosidase was determined, and the IC50 of the samples was calculated using nonlinear regression in Prism 9.5 software. 50 Value. Result as follows Figure 12 As shown. The formula for the inhibition rate of the sample against the enzyme is: In experiment A, phenylpyrrole compounds (compound 1 or 2) + α - Absorbance values ​​of the glucosidase group; background A: absorbance values ​​of the phenylpyrrole compound group (compound 1 or 2); control A: acarbose + α-propionate positive control. - Absorbance of the glucosidase group; A blank represents no added substance.

[0049] Figure 12 Codonopsis pilosula N and Codonopsis pilosula A and acarbose for α - IC50 glucosidase inhibitory activity 50 The value determination curve. Based on... Figure 12 It can be seen that the higher the concentrations of compounds 1 and 2, as well as acarbose, the higher the α-reactivity. - The higher the inhibition rate of glucosidase, the greater the α-inhibition rate of compound 1 at the same concentration. -The glucosidase inhibition rate of compound 1 was higher than that of compound 2, which was higher than that of acarbose; the IC50 of compound 1 was higher than that of compound 2. 50 The value was 67.9 μM, and the IC50 of compound 2 was... 50 The value was 81.1 μM, and the IC50 of acarbose was... 50 The value is 349.1 μM, indicating that compounds 1 and 2 extracted and isolated in this invention have excellent α-properties. - The inhibition rate of glucosidase has broad prospects for use in the preparation of hypoglycemic drugs and the treatment of diabetes.

[0050] This document uses specific examples to illustrate the principles and implementation methods of the present invention. The descriptions of the above embodiments are only for the purpose of helping to understand the method and core ideas of the present invention. Furthermore, those skilled in the art will recognize that, based on the ideas of the present invention, there will be changes in the specific implementation methods and application scope. Therefore, the content of this specification should not be construed as a limitation of the present invention.

Claims

1. A phenylpyrrole compound, characterized in that, The molecular formula is C 13 H 19 NO5, which is either codonopsis alkaloid N or codonopsis alkaloid A, has the following chemical structural formula: 、 ; Codonopsis pilosula N and Codonopsis pilosula A are epimers of each other.

2. The method for extracting and separating the phenylpyrrole compounds according to claim 1, comprising the following steps: Step 1: Extract the root of Codonopsis pilosula by reflux with ethanol, concentrate the extract to obtain an extract; Step 2: Elute the extract onto the macroporous adsorption resin sequentially with water and ethanol aqueous solution, collect the ethanol aqueous solution eluent, and concentrate it; Step 3: Load the concentrated ethanol-water eluent onto an MCI GEL column, use an alcohol-water gradient elution system, and collect the fractions. Step 4: Separate fraction Fr.6 by C18 reverse chromatographic column chromatography, using the first alcohol-water mobile phase for elution, to obtain fractions Fr.6-3 and Fr.6-4; the fraction Fr.6 is obtained by using an alcohol-water system with an alcohol volume fraction of 25%~28.5%; Step 5: Separate component Fr.6-3 by ODS C18 column chromatography, using the second alcohol-water mobile phase as the first elution to obtain codonopsis alkaloid N; separate component Fr.6-4 by Xunion C18 column chromatography, using the third alcohol-water mobile phase as the second elution to obtain codonopsis alkaloid A.

3. The extraction and separation method according to claim 2, characterized in that, In step one, the volume concentration of ethanol is 70-80%, and the dry weight of Codonopsis root to the amount of ethanol is 16kg:150-250L.

4. The extraction and separation method according to claim 2, characterized in that, In step two, the macroporous adsorption resin is D101 macroporous adsorption resin, and the volume concentration of ethanol in the ethanol aqueous solution is 15-25%.

5. The extraction and separation method according to claim 2, characterized in that, In step three, the alcohol-water system is a methanol-water system, and the gradient elution program is as follows: 0~30 min, methanol volume fraction is 0%; 30~210 min, methanol volume fraction increases from 0% to 32%; 210~211 min, methanol volume fraction increases from 32% to 40%; 211~240 min, methanol volume fraction increases from 40% to 95%; 240~270 min, methanol volume fraction is 95%; the flow rate of the gradient elution is 28~32 mL / min.

6. The extraction and separation method according to claim 2, characterized in that, In step four, the stationary phase of the C18 reverse-phase chromatography column is ODS C18; the first alcohol-water mobile phase is a methanol-water mobile phase; the elution is isocratic elution; the volume ratio of methanol to water in the methanol-water mobile phase is 11:89; the retention time of component Fr.6-3 is 15.093 min; and the retention time of component Fr.6-4 is 17.173 min.

7. The extraction and separation method according to claim 2, characterized in that, In step five, the second and third alcohol-water mobile phases are methanol-water mobile phases, the first and second elutions are isocratic elutions, the volume ratio of methanol to water in the methanol-water mobile phase is 5:95, the retention time of codonopsis alkaloid N is 9.282±0.2 min, the purity is >90%, and the yield is 8.4%; the retention time of codonopsis alkaloid A is 10.127±0.2 min, the purity is >90%, and the yield is 9.5%.

8. The phenylpyrrole compound of claim 1 or the phenylpyrrole compound obtained by the separation and extraction method according to any one of claims 2 to 7 in the preparation of α - Applications of glucosidase inhibitors.

9. The use of the phenylpyrrole compound of claim 1 or the phenylpyrrole compound obtained by the separation and extraction method of any one of claims 2 to 7 in the preparation of a drug for treating diabetes.

10. A pharmaceutical composition comprising a phenylpyrrole compound as described in claim 1 or a phenylpyrrole compound obtained by the separation and extraction method as described in any one of claims 2 to 7, and pharmaceutically acceptable excipients.